Core Viewpoint - The article emphasizes the commitment of Kasey to the Chinese market, highlighting its strategic initiatives to enhance patient accessibility to innovative medications and deepen collaborations with partners during the China International Import Expo (CIIE) [1][3][10]. Group 1: Company Strategy and Market Commitment - Kasey has seen a significant increase in product launches in China, surpassing other countries, and has expanded its workforce in China by 30% over the past two years, indicating its strategic focus on China as a key growth engine [1][6]. - The company aims to enhance patient access to innovative products through a "China to China," "China to Global," and "Global to China" strategy, reflecting its commitment to addressing unmet medical needs in the Chinese market [6][7]. - Kasey has signed a strategic cooperation agreement with JD Health to launch its respiratory product line, aiming to improve medication accessibility and patient adherence through digital channels [8][10]. Group 2: Product Innovation and Development - The focus of Kasey at the CIIE was the commercial launch of its ultra-fine particle ICS/LABA inhaler, which is the only one approved in China, designed to meet the specific needs of asthma patients [4][5]. - The inhaler features innovative technology with a median particle size of 1.4-1.5μm, achieving a lung deposition rate of 56% for asthma patients, addressing the clinical challenge of proper inhaler use [5][10]. - Kasey is actively exploring new pathways for respiratory disease management by leveraging partnerships with e-commerce platforms and retail pharmacies to enhance product accessibility [5][10]. Group 3: Collaboration and Partnerships - During the CIIE, Kasey announced a memorandum of cooperation with the China Rare Disease Alliance to improve rare disease management and patient accessibility [3][6]. - The collaboration with JD Health will extend beyond product sales to include disease education, online consultations, and smart chronic disease management, showcasing a comprehensive approach to patient care [10]. - Kasey is also collaborating with local companies like Haikang to develop innovative drugs for respiratory conditions, marking a significant shift in its global strategy [6][7].